Indian drugmaker Cipla announced on Friday the acquisition of two US-based drugmakers - InvaGen Pharma and Exelan Pharma - for $550 million (approximately Rs 3650cr). This acquisition will give the company scale in the US generics market through a wide range of product portfolio in CNS, CVS, anti-infectives, diabetes as well as other value-added generics, said Cipla in a statement.